TITLE: An International Longitudinal Natural History Study of Danon Disease

- Patients: Unique Cardiac Trajectories Identified Based on Sex and Heart Failure Outcomes
-

5 **AUTHORS' NAMES:** Kimberly N. Hong¹, Emily Eshraghian^{1,2}, Tarek Khedro^{1,3}, 6 Alessia Argirò^{1,4}, Jennifer Attias¹, Garrett Storm⁵, Melina Tsotras¹, Tanner Bloks⁵, 7 Isaiah Jackson⁵, Elijah Ahmad⁵, Sharon Graw⁵, Luisa Mestroni⁵, Quan M. Bui¹,

- Jonathan Schwartz⁶, Stuart Turner⁶, Eric D. Adler*¹, Matthew Taylor*⁵
- *****The authors contributed equally to the manuscript.
-

TOTAL WORD COUNT: 3,413

13 **AFFILIATIONS:** ¹University of California, San Diego, La Jolla, California; 14 ²University of Minnesota Medical School, Minneapolis, Minnesota; ³Royal 15 College of Surgeons in Ireland, Dublin, Ireland; ⁴Cardiomyopathy Unit, University 16 of Florence, Florence, Italy; ⁵University of Colorado Anschutz Medical Center, 17 Denver, Colorado; ⁶Rocket Pharmaceuticals Inc., New York, New York

 MEETING PRESENTATION: *American Heart Association, Scientific Sessions 2023*

-
- **FUNDING:** Grant MDA 67944.
-

 DISCLOSURES: AA and QBI report consulting fees from Lexeo Therapeutics. JS and ST are employees and shareholders of Rocket Pharmaceuticals. EDA serves as Chief Medical Officer and Head of Research for Lexeo Therapeutics, is a shareholder of Rocket Pharmaceuticals, Founder of Papillion Therapeutics, and Founder, Scientific board member, and shareholder of Corstasis Therapeutics. MT serves as principal investigator on a research grant from Rocket Pharmaceuticals. The remaining authors have nothing to disclose.

CORRESPONDING AUTHOR:

- Kimberly N. Hong, MD MHSA
- University of California San Diego, San Diego, California, USA
- 9434 Medical Center Dr, La Jolla, CA 92037
- knhong@health.ucsd.edu

ABSTRACT

- another after.
- **Conclusions:** In this largest longitudinal natural history study of DD to date, we
- confirmed that males present on average a decade earlier and demonstrate more
- progressive cardiac hypertrophy and heart failure than females. Of note, there may be a
- subset of females who are phenotypically similar to males with profound LV hypertrophy
- that appears to stabilize or regress prior to HF outcome. Correlations between structural
- changes including LV hypertrophy, dilation and dysfunction and disease progression
- may allow for risk stratification of Danon patients and refinement of treatment algorithms
- while also informing therapeutic trial design.

Abstract Word Count: 392

INTRODUCTION

 Danon disease (DD) is a rare X-linked dominant cardioskeletal myopathy caused by 76 mutations in the lysosome-associated membrane protein-2 ($LAMP2$) gene.¹ It is characterized by a severe cardiomyopathy associated with skeletal myopathy and cognitive impairment. DD in males is typically lethal without cardiac transplantation, and while disease severity is variable in females, there is a subset of females who require 80 cardiac transplantation at similar ages to males.²⁻⁵ As an X-linked disorder, disease course varies by sex, with males typically developing extracardiac symptoms early in childhood. Cardiac manifestations present soon after and reach end-stage in males by the second or third decade of life. Female extracardiac symptoms are variable, with cardiac manifestations in the 2nd or 3rd decade of life typically being the first symptoms.⁵⁻⁸ Understanding natural disease progression is critical to improving outcomes in DD patients, as it provides not only a basis for assessing the efficacy of treatments, but also allows appropriate identification of patients for evolving therapeutics. The purpose of this paper is to describe differences in disease progression as characterized by longitudinal changes in echocardiographic and laboratory parameters prior to death, heart transplantation or ventricular assist device in males and females with DD.

METHODS

 Data were from the International Danon Disease Registry that includes patients from the United States and Europe consented between 2005 and 2022. There were two enrolling sites in the United States, University of Colorado and University of California, San Diego. Patients were referred by their physician or self-referred through patient community and outreach sites including www.DanonDisease.org, https://rarediseases.org/rare-diseases/danon-disease/, and two Facebook groups (Danon Disease Support Group

and Danon Disease Support). All patients were required to have a history of positive

 genetic testing (defined as pathogenic or likely pathogenic *LAMP2* variations) or confirmed genealogy to a known DD carrier prior to enrollment. Specific genetic data was collected for 50% (n=60) of the patient cohort. Records were obtained from the first episode of care to the date of enrollment. These data include patients born between the years of 1943 and 2020. Data collected included demographics, clinical characteristics such as involvement of extracardiac systems and concomitant cardiac conditions, echocardiographic parameters, laboratory values, cardiovascular implantable electronic device (CIED) implantation and ablation. Specific echocardiographic parameters that were collected included left ventricular (LV) thickest wall which was defined as the largest measurement between septal and posterior wall thickness, LV ejection fraction (LVEF), LV end diastolic diameter (LVEDD), which is the distance measured between the LV septal and posterior walls in the parasternal view, and LV mass which was calculated using the Cube formula (LV mass=(0.8*1.04[(IVS+LVEDD+PWd)^3-LVEDD^3]+0.6 grams), 114 wherein LV measurements are in cm).⁹ Outcome measures include heart transplantation, left ventricular assist device and death. Z-scores were calculated for LV septal and posterior wall, LVEDD and LV mass measurements in patients with echocardiograms completed prior to the age of 18 years. Laboratory values, including skeletal muscle, cardiac, and liver biomarkers, were collected. These included creatine phosphokinase (mcg/L), brain natriuretic peptide

(pg/mL), aspartate transaminase (AST, IU/L), alanine aminotransferase (ALT, IU/L),

alkaline phosphatase (IU/L) and total bilirubin (mg/dL).

All data were analyzed with the statistical software package Stata 17 (Stata Corp,

College Station, TX). Continuous variables were reported as either mean with standard

 deviation or median with interquartile range depending on normality testing and compared with either Student's t-test or Wilcoxon Rank Sum non-parametric test as 126 appropriate. To compare categorical variables, the Pearson's X^2 was used. The conventional probability value of 0.05 or less was used to determine statistical significance. All reported *P-*values are two-sided. For longitudinal analysis, Wilcoxon Rank Sum testing was used to compare first and last echocardiograms and linear mixed models were used to test for trends in echocardiography parameters over time/age. For the echocardiography measures, separate mixed models were run for measures with pediatric z-scores (included echocardiograms completed prior to the age of 18 years of age) and for all values (included all echocardiograms). Age was the fixed effect, and the individual patient the random effect. For survival analysis, Kaplan-Meier analysis was used for time-to-HF event analysis, with log-rank test used to assess differences across sex. Patients alive at last follow-up were censored on the day of last known follow-up.

RESULTS

 The analysis included 116 DD patients and was stratified by sex: female (n=64, 55%) and male (n=52, 45%). [Table 1] Median age of diagnosis for the entire cohort was 15.2 years (10.0-25.2 years), and 21.9 years (15.0-34.9 years) and 12.4 years (7.1-15.6 years) for females and males respectively. Median age at last follow-up time for the entire cohort was 23.0 years (IQR: 16.5 – 34.5 years), and 32.0 years (IQR: 22.5 – 46.0 years) and 18.5 years (14.0 – 23.0 years) for females and males respectively. Median follow up time was 5.82 years (2.67 – 11.76 years) for the entire cohort, and 5.82 years (2.67 – 14.96 years) and 5.86 years (2.93 – 8.51 years) for females and males respectively. The majority of patients in the registry were White (72.4%). Regarding arrhythmia characteristics, 19.8% (n=23) of patients had WPW, 18.1% (n=21) had atrial fibrillation (AF) and 38.8% (n=45) of patients had a CIED; there were no differences in

 prevalence of WPW (p=0.429) or CIED (p=0.653) implantations between males and females. AF occurred more frequently in females compared to males (p=0.004). Within patients who received a CIED, 2 males (3.8%) were implanted with pacemakers alone; the remaining patients were implanted with an AICD, of which 5.2% (n=2) were for secondary prevention. *Heart Failure Outcomes* 156 The incidence of the HF outcome was higher in males compared to females ($p=0.031$), and actuarial median age of HF outcome was younger in males compared to females with median time to HF outcome being 25 years in males and 63 years in females (P<0.001). [Figure1] While age of HF outcome in males (19 years (16-23 years)) was numerically lower compared to females (26 years (14-39 years)) who did experience HF outcome, this did not reach statistical significance (p=0.162). This may be due to a possible bimodal distribution in age at which females experience a HF outcome [Figure 163 2]. Median age of HF outcome in females with HF outcome \geq 26yo (n=7) and <26yo (n=7) was 39 (28-47yrs) and 14 (11-20yrs) respectively (p=0.002). Additional analyses stratifying females by age of HF outcome are presented below.

Echocardiographic Parameter Analyses

 A total of 95 (82%) patients had echocardiographic results, of which 75 (92%) had serial echocardiograms. Ages of first echocardiogram in patients with serial echocardiograms were 15.9 years (11.3-19.9 years) and 25.8 years (17.0-42.2 years) in males and females respectively. Median time from first to last echocardiogram in all patients was 4.7 years (IQR: 1.1-8.9 years), and 4.2 years (IQR: 0.7-6.1 years) and 6.1 years (IQR 1.2-11.3 years) in males and females respectively.

yet experienced a HF outcome (<0.001). [Table 3, Figure 5] Notably, in the mixed effect

model of pediatric echocardiograms, LVH continues until the age of 18 years regardless

201 of HF outcome (p<0.001). In females, unlike males, there is regression in LV thickness 202 over time in both those who experience a HF outcome, as well as, those who do not. In 203 the mixed effect model of LV wall thickness in pediatric echocardiograms only, 204 regression in LV wall thickness was noted in females who experienced a HF outcome 205 (p<0.001), but not in females who did not (p=0.387). [Figure 5] LV mass increases in 206 males regardless of HF outcome and begins in childhood and continues through 207 adulthood. In females, LV mass does not change significantly with age, likely due to 208 progressive thinning and dilation that occurs over time in females. [Figure 6] In the 209 pediatric z-score analysis, mixed effect model showed decreasing LV mass in females 210 who experience a HF outcome (p=0.012). 211 212 *Female stratified analyses* 213 Given the results above, we chose to further evaluate outcomes specifically among 214 females. In stratified analyses of females by HF outcome before 26 years old (<26 yo, 215 n=7) and at or after 26 years old $(\geq 26$ yo, n=7), age of diagnosis was significantly earlier 216 (p=0.025) in the <26yo cohort (14 years (10 – 20 years)) compared to the \geq 26yo cohort 217 (34 years (28 – 40 years)). Regarding clinical characteristics, prevalence of CIED (86% 218 vs 43%, p=0.094) and WPW (43% vs 0%, p=0.051) were numerically higher in the $219 - 26$ yo compared to ≥ 26 yo groups. Analysis of echocardiographic parameters suggests 220 increased LV hypertrophy in the <26yo compared to \geq 26yo group, with higher numerical 221 values at both first and last echocardiogram [Table 6]. Notably, although all females 222 who reached a HF outcome met criteria for LV hypertrophy at some point during their

- 223 life, patients in the <26yo group developed more significant hypertrophy compared to
- 224 those in the ≧26yo (2.36cm (2.30 3.26 cm) vs 1.4cm (0.9 1.5 cm); p=0.020). In
- 225 regards to overall longitudinal change in LVWT, in the <26yo group there was no change
- 226 in LVWT as these females aged, while in the \geq 26yo, there was LV thinning over time.

 [Table 7] If longitudinal change in LVWT in the <26yo group was measured starting from the echocardiogram with the greatest LV hypertrophy, females in the <26yo group (mixed effects coefficient: -0.3258 (-0.434, -0.218); p<0.001) were noted to have 230 ventricular thinning similar to the \geq 26yo group prior to experiencing a HF outcome. At individual levels, some females (including those who experienced HF outcomes in the <26yo group) appear to have had progressive hypertrophy with subsequent decreases in LVWT and LVM. [Figures 5-7] LVEF decreased in both groups, however, the progression of LV dysfunction was more pronounced in the <26yo compared to the $235 \geq 26$ yo group. LVEDD increased in both groups, however, the rate of dilation over time 236 was higher in the <26yo compared to the \geq 26yo group. In longitudinal analysis, LV mass continued to increase in the <26yo group, while in the ≧26yo LV mass remained unchanged. [Table 7]

Laboratory Analyses

241 The availability of laboratory values differed by lab test and sex. For males, availability of laboratory values ranged from 44-63% and in females 31-50%. [Table 4] None of the skeletal muscle, cardiac and liver biomarkers changed between first and last measurement. First laboratory values in patients revealed higher CPK, AST, ALT and alkaline phosphatase in males compared to females (p-value<0.001). In longitudinal analyses by mixed effect models, in males, CPK decreased in patients who did not experience a HF outcome (p<0.001) and AST and ALT decreased in patients who experienced a HF outcome (p<0.001 and p=0.004 respectively). Alkaline phosphatase 249 decreased regardless of HF outcome in males $(p<0.01)$. In females, AST and alkaline phosphatase decreased in all patients regardless of HF outcome (p<0.02), and ALT 251 decreased only in females who did not experience a HF outcome (p=0.046). [Table 5]

253 **DISCUSSION**

Echocardiographic Changes Over Time

 A corollary to characterizing longitudinal changes in LV structure over time is how this 281 data can impact clinical decision making. Specific to our findings is utilizing changes in LVEF and structure to assist in patient management, risk stratification as well as identification of surrogate markers of disease progression and clinical outcomes. Our primary longitudinal findings are the differential changes in LV function and structure that may discriminate patients who will experience a HF outcome from those who will not. Specifically, while LVEF drops irrespective of sex and HF outcome over time, the degradation of LVEF is more accelerated in those who experience a HF outcome. Similarly, while LV dilation occurs regardless of sex and HF outcome, which may be due to age-appropriate growth in this patient population that includes pediatric and adult data, the rate of LV dilation is also higher in those who experience a HF outcome. This may be contributed to by decreases in LVEF and stabilization of LVH in males who experience a HF outcome and also observed thinning in females regardless of HF outcome. These findings suggest that LVEF and LVEDD may be used to predict HF outcome and can be used by clinicians to escalate surveillance intervals and risk stratify DD patients for advanced therapies. Notably, progressive disease in hypertrophic $$ cardiomyopathy is also marked by increasing LVEDD and also by decreased LVEF.¹¹

 A major difference in phenotypes between sexes is that in males who have not yet experienced HF outcome, LV hypertrophy continues. This suggests that eventual LVH stabilization may be a marker for end-stage disease in males particularly when paired with progressive LV dysfunction and dilation. The pattern of LV remodeling in this cohort of females was different, with LV thinning occurring over time regardless of HF outcome. Consistent with the aforementioned differences in LV remodeling between males and

Laboratory Changes Over Time

 Interpretation of laboratory values is limited by sample size, with majority of laboratory values presented having ~50% completion, and the selection bias in those who ended up getting repeat laboratory studies completed. To this end, interpretation of longitudinal

Clinical Trial Design

 Additionally, although cardiac transplantation remains the only therapeutic option with a survival benefit, a Phase I gene therapy trial in DD has completed and a Phase II AAV9 aene therapy trial is pending enrollment.¹⁶ Major barriers to designing a DD comparative effectiveness trial with a traditional control population include low disease prevalence, incidence of outcomes and treatment effect sizes. To mitigate the effect of these barriers, the FDA has encouraged: 1) non-traditional trial design, including the use of historical controls and 2) pathways for accelerated drug approval which include using surrogate endpoints that predict traditional clinical outcomes associated with improved 346 patient functional status, quality of life and survival.^{17,18} To this end, natural history studies are an important adjunct to understanding disease course and developing therapeutics that will impact disease progression and outcomes. The results from this study suggest that potential surrogate endpoints for therapeutic trials could include LVEF, LV mass, LVEDD and LV wall thickness in males, and LVEF, LVEDD and LV wall thickness in females. Additionally, because LV hypertrophy was a prominent feature in those experiencing a HF outcome, particularly in males and also females who experienced a HF outcome earlier in life, trial design including hypertrophy as an entry criteria can be considered.

 Limitations*.* While this study reports outcomes from the largest cohort of Danon Disease patients, the sample size remains small and limits generalizability. Patient registries often suffer from variability in data entry and due to the retrospective nature of the study and also standard of care data collection that spanned enrollment over several decades, data collection intervals and parameters were not consistent. Notably, echocardiography was obtained in >80 percent of the patient population, however, laboratory values were only collected in ~50%, with CPK and BNP only collected in ~30% of female patients. All patients included within the study had outcomes data collected though. Even with these limitations, this remains the largest cohort with longitudinal echocardiographic and laboratory data. **CONCLUSIONS** DD is a disease without disease-modifying therapies, although gene therapy trials are

underway. Understanding the natural history of DD will inform patient selection and trial

design for new therapies. Disease progression as characterized by changes in

echocardiographic parameters can differ by sex and HF outcome suggesting that

longitudinal changes in LV structure and function should be used for clinical risk

stratification and incorporated into clinical trial endpoints as surrogates of clinical

progression and end stage heart failure or death.

Funding: Investigator-initiated sponsor research agreement with Rocket

Pharmaceuticals.

379 **TABLES/FIGURES**

380 **Table 1. Summary statistics for patients stratified by sex.**

aloverter defibrillator, CIED: Cardiac Implantable Electri IQR: interquartile range, LVEF: left ventricular ejection fraction, LVAD: left ventricular assist device, TXP: heart transplant, WPW: Wolff-Parkinson-White

381 **Table 2. Echocardiographic measurements at first and last exam stratified by sex. Within and between sex comparisons**

382 **between first and last measurement were completed and p-values reported. Statistically significant p-values were bolded.**

383

385 **Table 3. Longitudinal trend analysis of echocardiographic parameters over time. Coefficients derived from mixed effect**

386 **regression models represent the magnitude of change in the parameter as patient ages.**

388 **Table 4. Laboratory measurements at first and last exam stratified by sex. Within and between sex comparisons between**

389 **first and last measurement were completed and p-values reported. Statistically significant p-values were bolded.**

391 **Table 5. Longitudinal trend analysis of laboratory parameters over time. Coefficients derived from mixed effect regression**

392 **models represent the magnitude of change in the parameter as patient ages.**

394 **Table 6. Echocardiographic measurements in females who experienced a HF outcome at first and last exam stratified by**

395 **age of HF outcome. Between group comparisons for first and last measurement were completed and p-values reported.**

397 **Table 7. Longitudinal trend analysis of echocardiographic parameters over time in female patients who experienced a HF**

- 398 **outcome stratified by age of HF outcome. Coefficients derived from mixed effect regression models represent the**
- 399 **magnitude of change in the parameter as patient ages.**
- 400

Figure 1. Kaplan Meier Time to HF Outcome Analysis Stratified by Sex

Figure 2. Histogram of age at heart failure outcome stratified by sex. There is a

suggestion of a bimodal distribution for HF outcome in females.

- **Figure 3.** LVEF changes over time, as represented by linear mixed effects regression
- plot and individual spaghetti plots, stratified by sex and HF outcome. In females
- experiencing HF outcome, mixed effects regression plot for patients experiencing HF
- outcome prior to the age of 26 years old was graphed.

Figure 4. LVEDD over time by sex and HF outcome

Figure 5. LV wall thickness measurement over time by sex and HF outcome. Thickest

422 **Figure. 6** LV Mass measurement over time by sex and HF outcome

- **Figure. 7** LVWT in females who experience HF outcome prior to 26 years of age at all
- time points and from time of thickest LVWT.

REFERENCES

- [1] Hong KN, Eshraghian EA, Arad M, Argirò A, Brambatti M, Bui Q, Caspi O, de Frutos
- F, Greenberg B, Ho CY, Kaski JP, Olivotto I, Taylor MRG, Yesso A, Garcia-Pavia P,
- Adler ED. International Consensus on Differential Diagnosis and Management of
- Patients With Danon Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023
- Oct 17;82(16):1628-1647.
- [2] Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med.
- 2011;13(6):563-568.
- [3] Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa
- JM, Saul JP, Ho CY, Seidman J, Seidman CE. Clinical outcome and phenotypic
- expression in LAMP2 cardiomyopathy. JAMA. 2009 Mar 25;301(12):1253-9. doi:
- 10.1001/jama.2009.371. PMID: 19318653; PMCID: PMC4106257.
- [4] Hong KN, Battikha C, John S, Lin A, Bui QM, Brambatti M, Storm G, Boynton K,
- Medina-Hernandez D, Garcia-Alvarez A, Castel MA, Garcia-Guereta L, Diez Lopez C,
- Perez-Gomez L, Miani D, Symanski JD, Taylor MR, Garcia-Pavia P, Adler ED. Cardiac
- Transplantation in Danon Disease. J Card Fail. 2022 Apr;28(4):664-669.
- [5] Lotan D, Salazar-Mendiguchía J, Mogensen J, et al. Clinical Profile of Cardiac
- Involvement in Danon Disease: A Multicenter European Registry. Circ Genomic Precis
- Med. 2020:660-670.
- [6] López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A et al. Clinical Findings and
- Prognosis of Danon Disease. An Analysis of the Spanish Multicenter Danon Registry.
- Rev Esp Cardiol (Engl Ed). 2019 Jun;72(6):479-486. English, Spanish. doi:
- 10.1016/j.rec.2018.04.035. Epub 2018 Aug 11. PMID: 30108015.

- [7] Brambatti M, Caspi O, Maolo A, Koshi E, Greenberg B, Taylor MRG, Adler ED.
- Danon disease: Gender differences in presentation and outcomes. Int J Cardiol. 2019 Jul 1;286:92-98.
- [8] Sugie K, Komaki H, Eura N, Shiota T, Onoue K, Tsukaguchi H, Minami N, Ogawa M,
- Kiriyama T, Kataoka H, Saito Y, Nonaka I, Nishino I. A Nationwide Survey on Danon
- Disease in Japan. Int J Mol Sci. 2018 Nov 8;19(11):3507.
- [9] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf
- FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH,
- Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for
- cardiac chamber quantification by echocardiography in adults: an update from the
- American Society of Echocardiography and the European Association of Cardiovascular
- Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14.
- [10] Cenacchi G, Papa V, Pegoraro V, Marozzo R, Fanin M, Angelini C. Review: Danon
- disease: Review of natural history and recent advances. Neuropathol Appl Neurobiol.
- 2020 Jun;46(4):303-322. [11] Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of
- disease progression in hypertrophic cardiomyopathy: an individualized approach to
- clinical staging. Circ Heart Fail. 2012 Jul 1;5(4):535-46.
- [12] Rigolli M, Kahn AM, Brambatti M et al. Cardiac Magnetic Resonance Imaging in
- Danon Disease Cardiomyopathy. JACC Cardiovasc Imaging. 2020 Sep 26:S1936-
- 878X(20)30728-2.
- [13] Rigolli M, Kahn A, Brambatti M et al. Cardiomyopathy characterization and risk-
- stratification by cardiac magnetic resonance in Danon Disease. Journal of the American
- College of Cardiology. 2020 Mar 24;75(11 Supplement 1):1681.
- [14] Wei X, Zhao L, Xie J, Liu Y, Du Z, Zhong X, Ye W, Wang Y, Chen Y, Lu M, Liu H.
- Cardiac Phenotype Characterization at MRI in Patients with Danon Disease: A
- Retrospective Multicenter Case Series. Radiology. 2021 May;299(2):303-310.

- [15] Bui QM, Hong KN, Kraushaar M, Ma GS, Brambatti M, Kahn AM, Battiha CE,
- Boynton K, Storm G, Mestroni L, Taylor MRG, DeMaria AN, Adler EA. Myocardial Strain
- and Association With Clinical Outcomes in Danon Disease: A Model for Monitoring
- Progression of Genetic Cardiomyopathies. J Am Heart Assoc. 2021 Dec
- 7;10(23):e022544. doi: 10.1161/JAHA.121.022544. Epub 2021 Nov 30. PMID:
- 34845930; PMCID: PMC9075351.
- [16] https://clinicaltrials.gov/study/NCT06092034 [visited 11/11/2023]
- [17] Rare Diseases: Natural History Studies for Drug Development. FDA Guidance
- Document. March 2019. FDA Guidance for Industry. March 2019.
- https://www.fda.gov/media/122425/download (accessed 11/11/2023)
- [18] Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. FDA. 23
- February 2018. https://www. fda.gov/patients/learn-about-drug-and-device-
- approvals/fast-track-breakthrough-therapy-accelerated-approval priority-review
- (accessed 11/11/2023)